PCSK9 Inhibitors: For Whom, When, and Why

PCSK9 Inhibitors: For Whom, When, and Why is organized by Med-IQ and will be held from Jul 17, 2018 - Jul 16, 2019.

The target audience for this medical event is intended for cardiologists, endocrinologists, primary care physicians, physician assistants, advanced practice nurses, pharmacists, and other healthcare professionals involved in the care of patients with elevated cholesterol levels. This CME Conference has been approved for a maximum of 0.5 AMA PRA Category 1 Credits/0.5 contact hour (0.05 CEUs).

Course Description:
In this audiocast, expert faculty discusses current clinical evidence regarding the benefit of adding a PCSK9 inhibitor to statin therapy in patients with cardiovascular risk and dyslipidemia. Additionally, key criteria for selecting patients for PCSK9 inhibitor therapy as well as determining optimal timing for initiating treatment are explored.

Course Objectives:
• Describe clinical trial data for PCSK9 inhibitor therapeutics
• Compare guideline recommendations when choosing which patients should receive PCSK9 inhibitors
• Discuss the patient groups that would most benefit from PCSK9 inhibitor therapy

Additional details will be posted as soon as they are available.